(Total Views: 752)
Posted On: 08/22/2022 4:07:29 PM
Post# of 156272
“Lenacapavir could face competition from another investigational treatment, leronlimab, currently being developed by CytoDyn (OTCMKTS: CYDY). Also in the mix is ViiV Healthcare’s cabotegravir, an integrase inhibitor. Cabotegravir-based options are projected to generate the bulk of sales in the injectables segment, says GlobalData.“
https://www.thepharmaletter.com/article/gilea...g-sunlenca
https://www.thepharmaletter.com/article/gilea...g-sunlenca
(6)
(0)
Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
